Skip to main content

How can we help you?

  • Deal or case news
  • 28-07-2015

On 27 July 2015, Teva Pharmaceutical Industries announced its agreement with Allergan to acquire Allergan’s Generic Drug Unit and its withdrawal of its expression of interest to acquire Mylan.  In a public statement, Mylan's Executive Chairman Robert J. Coury congratulated Teva on its agreement with Allergan and stated that Mylan’s strategic focus including its commitment to acquire Perrigo Company remains unchanged.

NautaDutilh represents Mylan in connection with both the successful takeover defence against Teva and the public offer for Perrigo. The NautaDutilh team is led by Christiaan de Brauw (M&A) together with Paul Olden (Litigation), Elizabeth van Schilfgaarde (Finance), Chris Warner (tax), Petra Zijp (capital markets) and Paul van der Bijl (Notarial), and further consists of Frans Overkleeft, Matthijs Noome, Jules van de Winckel, Ernst van der Touw, Stefan Wissing (all corporate), Jochem Polderman, Wouter Wehmeijer and Dewi Walian (equity capital markets), Catrien Rozeman (Finance NY office) and Nina Kielman (tax).

NautaDutilh works alongside Stibbe's litigation and anti-trust team, US firm Cravath, Swaine & Moore LLP, Irish firm Arthur Cox and Israeli firm Meitar Liquornik Geva Leshem Tal.

Cookie notice

We care about your privacy. We only use cookies strictly necessary to ensure the proper functioning of our website. You can find more information on cookies and on how we handle your personal data in our Privacy and Cookie Policy.